Medical Technology

News

• • Ad hoc 2025

  Cicor is continuing to grow in double digits – successful integration and M&A activities are strengthening the growth trend

  Ad hoc announcement pursuant to Art. 53 LR

  04/15/2025

  Bronschhofen, April 15, 2025 – The Cicor Group (SIX Swiss Exchange: CICN) has made a successful start to the 2025 business year. In the first quarter, sales increased by 22.2% to CHF 131.1 million (Q1/2024: CHF 107.3 million), while order intake increased by 29.1% year-on-year to CHF 125.8 million. This growth was mainly driven by the contributions of the companies acquired in the previous year. During the first quarter Cicor has continued to execute on its growth strategy: The acquisition of Profectus Solutions was completed and the agreement to acquire the shares of MADES was signed.

  Read more

  Read more
• • Ad hoc 2025

  Cicor expands into Spain – Acquisition of MADES strengthens Cicor's pan-European leadership in the Aerospace & Defence sector

  Ad hoc announcement pursuant to Art. 53 LR

  04/04/2025

  Bronschhofen, 4 April 2025 - Cicor Group (SIX Swiss Exchange: CICN) today announces that it has signed an agreement to acquire 100 % of the shares of Spanish electronics company Malaga Aerospace, Defense & Electronics Systems S.A.U. (MADES). With this planned acquisition, Cicor continues to build the leading pan-European platform for electronics design and manufacturing services for the fast-growing European defence market. Furthermore, entering Spain expands the addressed market of Cicor in its chosen applications.

  Read more

  Read more
• • Ad hoc 2025

  Cicor continues to grow – sales and profits at record levels thanks to strategic expansion

  Ad hoc announcement pursuant to Art. 53 LR

  03/06/2025

  Bronschhofen, 6 March, 2025 – The Cicor Group (SIX Swiss Exchange: CICN) looks back on an exceptionally successful year 2024. Significant market share gains and steadily increasing profit margins at all levels demonstrate the consistent execution of Cicor’s strategy. Earnings per share rose to CHF 6.20 (2023 restated: CHF 2.66), and free cash flow remained very positive even after accounting for acquisitions completed during the reporting year. The new strategy, under the motto "Creating Together", paves the way towards the sales target of at least CHF 1 billion by 2028, positioning Cicor as the leading pan-European electronics developer and manufacturer in the fields of medical technology, aerospace and defence, and industrial applications.

  Read more

  Read more
• Load more